The nonstaff members of IAS–USA Antiretroviral Guidelines Panel are volunteers and are not compensated for their role in overseeing the program. Listed below are the IAS–USA Antiretroviral Guidelines Panel members and their financial relationships with commercial interests within the past 12 months from the date of disclosure.


Chair

Michael S. Saag, MD
Professor of Medicine
University of Alabama at Birmingham
Birmingham, Alabama

Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc and ViiV Healthcare. (Updated 03/29/19)


Members

Constance A. Benson, MD
Professor of Medicine
University of California San Diego
San Diego, California

Dr Benson has served on advisory and data monitoring boards for GlaxoSmithKline/ViiV Healthcare and received research grants awarded to her institution from Gilead Sciences, Inc. Her spouse has served as a consultant to CytoDyn, Gilead Sciences, Inc, Pfizer, and Vir Biotechnology; has received grant support from Gilead Sciences, Inc; and holds stock or stock options in Antiva Biosciences and CytoDyn. (Updated 04/29/19)

Rajesh T. Gandhi, MD
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Dr Gandhi has served as a consultant or advisor to Merck & Co, Inc, and Gilead Sciences, Inc, and received educational grants to his institution from ViiV Healthcare, Janssen Therapeutics, Theratechnologies, and Gilead Sciences, Inc. (Updated 04/17/19)

Jennifer F. Hoy, MBBS, FRACP
Professor of Medicine
Monash University
Melbourne, Australia

Dr Hoy has served as an advisor for payment to her institution for Merck & Co, Inc, ViiV Healthcare, and Gilead Sciences, Inc. (Updated 07/24/18)

Raphael J. Landovitz, MD
Associate Professor of Medicine
University of California Los Angeles
Los Angeles, California

Dr Landovitz has served as a consultant to Merck & Co, Inc and Gilead Sciences, Inc. (Updated 04/25/19)

Michael J Mugavero, MD, MHSc
Associate Professor of Medicine
University of Alabama at Birmingham
Birmingham, Alabama

Dr Mugavero has served as a scientific advisor for Gilead Sciences, Inc. (Updated 07/24/18)

Paul E. Sax, MD
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Dr Sax has served as a consultant or advisor to GlaxoSmithKline/ViiV, Janssen Therapeutics, Merck & Co, Inc, and Gilead Sciences, Inc. He has received nonfinancial support from Bristol-Myers Squibb and grant support paid to his institution from Gilead Sciences, Inc, and GlaxoSmithKline/ViiV. (Updated 07/24/18)

Davey M. Smith, MD
Professor  of Medicine
University of California San Diego
San Diego, California

Dr Smith has served as a consultant to Gilead Sciences, Inc, Merck & Co, Inc, and the AIDS Healthcare Foundation, and received grant support awarded to his institution from ViiV Healthcare. (Updated 07/24/18)

Melanie A. Thompson, MD
Principal Investigator
AIDS Research Consortium of Atlanta
Atlanta, Georgia

Dr Thompson’s institution has received grants for research from Bristol-Myers Squibb, CytoDyn, Inc, Frontier Biotechnologies, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, TaiMed Biologics, Inc, and ViiV Healthcare. (Updated 03/22/19)

Susan P. Buchbinder, MD
Clinical Professor of Medicine and Epidemiology
University of California San Francisco
San Francisco, California

Dr Buchbinder has participated in research trials that received provision of medicines from Gilead Sciences, Inc. (Updated 04/12/19)

Carlos del Rio, MD
Professor of Global Health
Rollins School of Public Health
Professor of Medicine
Emory University School of Medicine
Atlanta, Georgia

Dr del Rio has no relevant financial affiliations to disclose. (Updated 05/17/19)

Joseph J. Eron, MD
Professor of Medicine and Epidemiology
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Dr Eron has served as an ad hoc consultant to Janssen Therapeutics, ViiV Healthcare, Merck & Co, Inc, and Gilead Sciences, Inc. His institution receives contracts for clinical research on which Dr Eron is the local principal investigator from Janssen Therapeutics, ViiV Healthcare, and Gilead Sciences, Inc. (Updated 04/29/19)

Gerd Fätkenheuer, MD
Professor
Division of Haemetology, Immunology, Infectiology, Intensive Care, and Oncology
University of Cologne
Cologne, Germany

Dr Fätkenheuer has received grant support from the German Center for Infection Research. (Updated 07/24/18)

Huldrych F. Günthard, MD
Professor of Infectious Diseases
University Hospital Zurich
Zurich, Switzerland

Dr Günthard has served as a consultant to Merck & Co, Inc, ViiV Healthcare, Sandoz, Teva, and Gilead Sciences, Inc and received research grants from the Swiss National Science Foundation, Systems.X (HIV.X), Swiss HIV Cohort Study, the Yvonne Jacob Foundation, and Gilead Sciences, Inc. (Updated 03/27/2019)

Jean-Michel Molina, MD
Professor of Infectious Diseases
University of Paris Diderot
Paris, France

Dr Molina has received grant support paid to his institution from Gilead Sciences, Inc, and served as a consultant to Merck & Co, Inc, Gilead Sciences, Inc, ViiV Healthcare, Bristol-Myers Squibb, Janssen Therapeutics, and Teva. (Updated 07/24/18)

Donna M. Jacobsen, BS
Executive Director/President
International Antiviral SocietyUSA
San Francisco, California

Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 05/23/19)

Paul A. Volberding, MD
Professor of Medicine
University of California San Francisco
San Francisco, California

Dr Volberding has served on data and safety monitoring boards for Merck & Co, Inc. (Updated 05/23/19)